Regen BioPharma Develops Novel Means of Using CAR-T Cell Immunotherapy to Attack Solid Tumors

Regen BioPharma, Inc. announced the development of a novel immunotherapy for treatment of solid tumors. The current approach developed by the company involves initial treatment of the tumor microenvironment with cells of the innate immune system called CAR-M and CAR-NK cells.